Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 1 2

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 2

Conditions

Glioblastoma 3Breast Neoplasms 3Brain Neoplasms 3Recurrence 2Multiple Myeloma 2Leukemia, Myelomonocytic, Chronic 2Gliosarcoma 2Breast Neoplasms, Male 2Squamous Cell Carcinoma of Head and Neck 1Myeloproliferative Disorders 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Inflammatory Breast Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Congenital Abnormalities 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Temozolomide 69Radiotherapy 30Bevacizumab 24Carboplatin 13pembrolizumab 12Radiation 11Carmustine 8Irinotecan 7temsirolimus 6Surgical Procedures, Operative 6Radiosurgery 6Erlotinib Hydrochloride 6atezolizumab 5Vorinostat 5Sirolimus 5Radiotherapy, Intensity-Modulated 5Nivolumab 5Lomustine 5Everolimus 5fludarabine 4Radiotherapy, Conformal 4Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Aminolevulinic Acid 4tipifarnib 3Sorafenib 3Paclitaxel 3IL13-PE38 3Granulocyte-Macrophage Colony-Stimulating Factor 3Gemcitabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Glioblastoma × tipifarnib × Clear all
NCT00050986 2020-09-22

Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme

M.D. Anderson Cancer Center

Phase 1/2 Completed
55 enrolled 6 charts
CNS

Brain Neoplasms, Central Nervous System Diseases, Glioblastoma

NCT00335764 2018-07-02

Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

National Cancer Institute (NCI)

Phase 1/2 Completed
92 enrolled 24 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00005859 2018-06-26

Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
136 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡